Mira Pharmaceuticals, Inc. (MIRA): Total Liabilities
$702.1K
As of 2025-12-31
$40.8K
As of 2026-06-30
-21.6%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $702.1K | -2.9% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $723.3K | +29.6% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $558.1K | -61.6% | 2025-03-28, Balance as of period end |
| 2022-12-31 | $1.45M | n/a | 2024-04-01, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Mira Pharmaceuticals, Inc. (MIRA) | 2025-12-31 | $702.1K | -2.9% |
| MetaVia Inc. (MTVA) | 2025-12-31 | $5.79M | -30.5% |
| Decoy Therapeutics Inc. (DCOY) | 2025-12-31 | $5.17M | +241.9% |
| Lantern Pharma Inc. (LTRN) | 2025-12-31 | $4.50M | +2.7% |
| NewcelX Ltd. (NCEL) | 2025-12-31 | $4.20M | -52.9% |
| Curanex Pharmaceuticals Inc (CURX) | 2025-12-31 | $361.0K | n/m |
| Revelation Biosciences, Inc. (REVB) | 2025-12-31 | $2.72M | +42.2% |
| Traws Pharma, Inc. (TRAW) | 2025-12-31 | $11.25M | -80.1% |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | 2025-12-31 | $8.22M | +357.5% |
Compare MIRA, MTVA, DCOY, LTRN side by side · Screen every company in Pharmaceutical Preparations ↗